Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections

References

• Gratwohl A, Baldomero H, Aljurf M, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303(16):1617–1624.
   PubMed Web of Science ®Google Scholar
• Ferrara JL, Levine JE, Reddy P, et al. Graft-versus-host disease. Lancet. 2009;373(9674):1550–1561.
   PubMed Web of Science ®Google Scholar
• Boyiadzis M, Arora M, Klein JP, et al. Impact of chronic graft-versus-host disease on late relapse and survival on 7,489 patients after myeloablative allogeneic hematopoietic cell transplantation for leukemia. Clin Cancer Res. 2015;21(9):2020–2028.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from gruppo italiano trapianti midollo osseo (GITMO). Blood. 2001;98(10):2942–2947.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Lamparelli T, Barisione G, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant. 2006;12(5):560–565.
   PubMed Web of Science ®Google Scholar
• Walker I, Panzarella T, Couban S, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol. 2016;17(2):164–173.
   PubMed Web of Science ®Google Scholar
• Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855–864.
   PubMed Web of Science ®Google Scholar
• Socie G, Schmoor C, Bethge WA, et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood. 2011;117(23):6375–6382.
   PubMed Web of Science ®Google Scholar
• Soiffer RJ, Kim HT, McGuirk J, et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-Lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. J Clin Oncol. 2017;35(36):4003–4011.
   PubMed Web of Science ®Google Scholar
• Admiraal R, Nierkens S, de Witte MA, et al. Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis. Lancet Haematol. 2017;4(4):e183–e91.
   PubMed Web of Science ®Google Scholar
• Kennedy VE, Chen H, Savani BN, et al. Optimizing antithymocyte globulin dosing for unrelated donor allogeneic hematopoietic cell transplantation based on recipient absolute lymphocyte count. Biol Blood Marrow Transplant. 2018;24(1):150–155.
   PubMed Web of Science ®Google Scholar
• Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–650.
   PubMed Web of Science ®Google Scholar
• Luznik L, O'Donnell PV, Fuchs EJ. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012;39(6):683–693.
   PubMed Web of Science ®Google Scholar
• Bashey A, Zhang X, Sizemore CA, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol. 2013;31(10):1310–1316.
   PubMed Web of Science ®Google Scholar
• El Fakih R, Hashmi SK, Ciurea SO, et al. Post-transplant cyclophosphamide use in matched HLA donors: a review of literature and future application. Bone Marrow Transplant. 2020;55(1):40–47.
   PubMed Web of Science ®Google Scholar
• Luznik L, Bolanos-Meade J, Zahurak M, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010;115(16):3224–3230.
   PubMed Web of Science ®Google Scholar
• Luznik L, Fuchs EJ. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res. 2010;47(1–3):65–77.
   PubMed Web of Science ®Google Scholar
• Bashey A, Zhang MJ, McCurdy SR, et al. Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell-replete haploidentical donor transplantation using post-transplant cyclophosphamide. J Clin Oncol. 2017;35(26):3002–3009.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wu DP, Liu QF, et al. Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients. J Hematol Oncol. 2019;12(1):88.
   PubMed Web of Science ®Google Scholar
• Yang J, Jiang J, Cai Y, et al. Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study. Bone Marrow Transplant. 2019;54(7):1049–1057.
   PubMed Web of Science ®Google Scholar
• Dulery R, Bastos J, Paviglianiti A, et al. Thiotepa, busulfan, and fludarabine conditioning regimen in T cell-replete HLA-haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25(7):1407–1415.
   PubMed Web of Science ®Google Scholar
• Salas MQ, Prem S, Atenafu EG, et al. Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD. Bone Marrow Transplant. 2020;55(9):1773–1783.
   PubMed Web of Science ®Google Scholar
• Salas MQ, Prem S, Atenafu EG, et al. Reduced intensity allogeneic stem cell transplant with anti-thymocyte globulin and post-transplant cyclophosphamide in acute myeloid leukemia. Eur J Haematol. 2019;103(5):510–518.
   PubMed Web of Science ®Google Scholar
• Law AD, Salas MQ, Lam W, et al. Reduced-Intensity conditioning and dual T lymphocyte suppression with antithymocyte globulin and post-transplant cyclophosphamide as graft-versus-Host disease prophylaxis in haploidentical hematopoietic stem cell transplants for hematological malignancies. Biol Blood Marrow Transplant. 2018;24(11):2259–2264.
   PubMed Web of Science ®Google Scholar
• Deotare U, Atenafu EG, Loach D, et al. Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation. Bone Marrow Transplant. 2018;53(3):361–365.
   PubMed Web of Science ®Google Scholar
• Scott BL, Pasquini MC, Logan BR, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35(11):1154–1161.
   PubMed Web of Science ®Google Scholar
• Hamadani M, Mohty M, Kharfan-Dabaja MA. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia. Cancer Control. 2011;18(4):237–245.
   PubMed Web of Science ®Google Scholar
• Valcarcel D, Martino R, Caballero D, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol. 2008;26(4):577–584.
   PubMed Web of Science ®Google Scholar
• Santoro N, Labopin M, Ciceri F, et al. Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia 45 years of age and over. Cancer. 2019;125(9):1499–1506.
   PubMed Web of Science ®Google Scholar
• Zilberberg J, Feinman R, Korngold R. Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation. Biol Blood Marrow Transplant. 2015;21(6):1000–1007.
   PubMed Web of Science ®Google Scholar
• Sweeney C, Vyas P. The graft-versus-leukemia effect in AML. Front Oncol. 2019;9:1217.
   PubMed Web of Science ®Google Scholar
• Armand P, Kim HT, Logan BR, et al. Validation and refinement of the disease risk index for allogeneic stem cell transplantation. Blood. 2014;123(23):3664–3671.
   PubMed Web of Science ®Google Scholar
• Khoury HJ, Loberiza FR, Jr., Ringden O, et al. Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood. 2006;107(4):1712–1716.
   PubMed Web of Science ®Google Scholar
• de Koning C, Gabelich JA, Langenhorst J, Admiraal R, et al. Filgrastim enhances T-cell clearance by antithymocyte globulin exposure after unrelated cord blood transplantation. Blood Adv. 2018;2(5):565–574.
   PubMed Web of Science ®Google Scholar
• Sloand EM, Kim S, Maciejewski JP, et al. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood. 2000;95(7):2269–2274.
   PubMed Web of Science ®Google Scholar
• Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008;112(12):4371–4383.
   PubMed Web of Science ®Google Scholar
• Hobbs GS, Perales MA. Effects of T-Cell depletion on allogeneic hematopoietic stem cell transplantation outcomes in AML patients. J Clin Med. 2015;4(3):488–503.
   PubMed Web of Science ®Google Scholar
• Admiraal R, van Kesteren C, Jol-van der Zijde CM, et al. Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. Lancet Haematol. 2015;2(5):e194–e203.
   PubMed Web of Science ®Google Scholar
• Nishihori T, Al-Kadhimi Z, Hamadani M, et al. Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations. Immunotherapy. 2016;8(4):435–447.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Bernardo ME, Bertaina A, et al. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(8):1126–1136.
   PubMed Web of Science ®Google Scholar
• Podgorny PJ, Ugarte-Torres A, Liu Y, et al. High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lymphoproliferative disorder. Biol Blood Marrow Transplant. 2010;16(7):915–926.
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433–2444.
   PubMed Web of Science ®Google Scholar
• Camargo JF, Komanduri KV. Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther. 2017;10(4):233–238.
   PubMedGoogle Scholar
• Stocker N, Labopin M, Boussen I, et al. Pre-emptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes. Bone Marrow Transplant. 2020;55(3):586–594.
   PubMed Web of Science ®Google Scholar
• Basso S, Compagno F, Zelini P, et al. Harnessing T cells to control infections after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2020;11(567531):567531.
   PubMed Web of Science ®Google Scholar
• Boelens JJ, Hosszu KK, Nierkens S. Immune monitoring after allogeneic hematopoietic cell transplantation: toward practical guidelines and standardization. Front Pediatr. 2020;8:454(1–7).
   Google Scholar
• Dulery R, Menard AL, Chantepie S, et al. Sequential conditioning with thiotepa in T cell-replete hematopoietic stem cell transplantation for the treatment of refractory hematologic malignancies: comparison with matched related, haplo-mismatched, and unrelated donors. Biol Blood Marrow Transplant. 2018;24(5):1013–1021.
   PubMed Web of Science ®Google Scholar
• Kunacheewa C, Owattanapanish W, Jirabanditsakul C, et al. Post-transplant cyclophosphamide and thymoglobulin, a graft-versus-host disease prophylaxis in matched sibling donor peripheral blood stem cell transplantations. Cell Transplant. 2020;29:963689720965900.
   PubMed Web of Science ®Google Scholar
• Bolanos-Meade J, Fuchs EJ, Luznik L, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012;120(22):4285–4291.
   PubMed Web of Science ®Google Scholar